Last reviewed · How we verify

The Royal Ottawa Mental Health Centre — Portfolio Competitive Intelligence Brief

The Royal Ottawa Mental Health Centre pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Children's Hospital Medical Center, Cincinnati · 1 shared drug class
  2. Hospital de Clinicas de Porto Alegre · 1 shared drug class
  3. Oregon Health and Science University · 1 shared drug class
  4. Orient Pharma Co., Ltd. · 1 shared drug class
  5. Pfizer · 1 shared drug class
  6. St. Louis University · 1 shared drug class
  7. UCB Pharma · 1 shared drug class
  8. University of California, San Francisco · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for The Royal Ottawa Mental Health Centre:

Cite this brief

Drug Landscape (2026). The Royal Ottawa Mental Health Centre — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-royal-ottawa-mental-health-centre. Accessed 2026-05-17.

Related